Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial

The Lancet Infectious Diseases

Volumn 13, Issue 1, 2013, Pages 27-35

  Ruslami, Rovina ^a   Ganiem, A Rizal ^a   Dian, Sofiati ^a   Apriani, Lika ^a   Achmad, Tri Hanggono ^a   van der Ven, Andre J ^b   Borm, George ^b   Aarnoutse, Rob E ^b   Van Crevel, Reinout ^b  

^a Hasan Sadikin Hospital   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CARDIOTOXICITY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDONESIA; MALE; MIDDLE AGED; QUINOLINES; RIFAMPIN; TUBERCULOSIS, MENINGEAL; YOUNG ADULT;

EID: 84871082520     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70264-5     Document Type: Article

References (28)

1. Ganiem AR, Parwati I, Wisaksana R, et al. The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study. AIDS 2009, 23:2309-2316.
2. Torok ME, Nguyen DB, Tran TH, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 2011, 6:e27821.
3. Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS 2007, 21:373-374.
4. Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005, 192:79-88.
5. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003, 47:2118-2124.
6. van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment?. Clin Infect Dis 2011, 52:e194-e199.
7. Donald PR Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010, 90:279-292.
8. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007, 51:2546-2551.
9. Steingart KR, Jotblad S, Robsky K, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011, 15:305-316.
10. Heemskerk D, Day J, Chau TT, et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials 2011, 12:25.
11. Lubasch A, Keller I, Borner K, Koeppe P, Lode H Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000, 44:2600-2603.
12. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007, 51:576-582.
13. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-338.
14. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
15. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
16. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 2008, 61:1328-1331.
17. Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009, 49:1080-1082.
18. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004, 190:1642-1651.
19. Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 2007, 51:4261-4266.
20. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007, 45:1001-1007.
21. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010, 10:803-812.
22. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741-1751.
23. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011, 52:1374-1383.
24. van Crevel R, Nelwan RH, Borst F, et al. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers. Int J Tuberc Lung Dis 2004, 8:500-503.
25. Peloquin CA Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169-2183.
26. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011, 55:3244-3253.
27. Ruslami R, Nijland HMJ, Alisjahbana B, Aarnoutse R, van Crevel R. Comparison of oral versus intravenous rifampicin in Indonesian pulmopnary tuberculosis patients. First International Workshop on Clinical Pharmacology of Tuberculosis Drugs; Toronto, ON, Canada; May 15, 2008. (abstr 10).
28. Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L Efficacy of four different moxifloxacin-based triple therapies for first-line H pylori treatment. Dig Liver Dis 2010, 42:110-114.